EPA

EPA Basic information
Product Name:EPA
Synonyms:5C,8C,11C,14C,17C-EICOSAPENTAENOIC ACID;5,8,11,14,17-EICOSAPENTAENOIC ACID;5Z,8Z,11Z,14Z,17Z-EICOSAPENTAENOIC ACID;ALL CIS-5,8,11,14,17-EICOSAPENTAENOIC ACID;ALL CIS 5-8-11-14-17 EPA;ALL CIS-5,8,11,14,17-ICOSAPENTAENOIC ACID;C20:5 (ALL CIS-5,8,11,14,17) ACID;C20:5 OMEGA-3
CAS:73167-03-0
MF:C20H29O2.Na
MW:324.44
EINECS:
Product Categories:Lipoxygenase (5-)Unsaturated fatty acids and derivatives;LipoxygenaseEnzyme Inhibitors by Enzyme;Omega 3 fatty acids and derivativesBiochemicals Found in Plants;Arachidonic Acid Cascade;Enzyme Inhibitors;L to;Lipids;Polyunsaturated
Mol File:73167-03-0.mol
EPA Structure
EPA Chemical Properties
Melting point −54-−53 °C(lit.)
density 0.943 g/mL at 25 °C(lit.)
refractive index n20/D 1.4977(lit.)
storage temp. -20°C
solubility Ethanol: 1.5 mg/ml; Ethanol:PBS(pH 7.2) (1:5): 0.5 mg/ml
form waxy solid
color white
Safety Information
Hazard Codes C
Risk Statements 34
Safety Statements 26-36/37/39-45
RIDADR UN 3265 8/PG 3
WGK Germany 3
8-10-23
MSDS Information
ProviderLanguage
SigmaAldrich English
EPA Usage And Synthesis
Usesreduces thromboxane A2 production and platelet aggregation, inhibits 5-lipoxygenase and prevents arteriosclerosis.
Usescis-5,8,11,14,17-Eicosapentaenoic acid sodium salt has been used:
  • to study its effect on the pathology of lupus in drug-induced and spontaneous mouse models
  • to pretreat mouse alveolar macrophages to study the effect/relationship between amiodarone and eicosapentaenoic acid (EPA) concerning the cytokine release
  • to examine if pharmacological correction with EPA supplementation might restore autophagic flux and reduce renal lipotoxicity in mice
General DescriptionEicosapentaenoic acid (EPA)/timnodonic acid is an omega-3 polyunsaturated fatty acid (PUFA). This long-chain fatty acid is mainly found in fish oil.
Biochem/physiol ActionsEicosapentaenoic acid (EPA) possesses anti-hyperglycemic, anti-oxidant, anti-hyperlipidemic, and anti-inflammatory properties. It aids in improving vasoreactivity. EPA is capable of suppressing vascular smooth muscle proliferation. It ameliorates pulmonary hypertension by preventing Fyn kinase activity. EPA exhibits a beneficial effect on lipid metabolism. It is used to treat hypercholesterolemia and atherosclerosis.
EPA Preparation Products And Raw materials
EPA 5,8,11,14,17-EICOSAPENTAENOIC ACID,5,8,11,14,17-EICOSAPENTAENOIC ACID EPA II PEROXIDASE PROTECTION BUFFER EPA METHOD 8330 CALIBRATION MIX B,EPA METHOD 8330 CALIBRATION MIX A HALOGENATED NON-AROMATIC VOLATILES MIX 1, EPA 8021B (+/-)-12-HYDROXY-5Z,8Z,10E,14Z,17Z-EICOSAPENTAENOIC ACID 12R-HYDROXY-5Z,8Z,10E,14Z,17Z-EICOSAPENTAENOIC ACID AROMATIC VOLATILES MIX 1, EPA 8021B 5S-HYDROXY-6E,8Z,11Z,14Z,17Z-EICOSAPENTAENOIC ACID [1-14C] EPA METHOD 1666 SECONDARY STOCK STANDARD 2 5,8,11,14,17-EICOSAPENTAENOIC ACID [1-14 C],EICOSAPENTAENOIC ACID, 5,8,11,14,17-[1-14C],5,8,11,14,17-EICOSAPENTAENOIC ACID [1-14 C] EICOSAPENTAENOIC ACID, 5,8,11,14,17[5,6,8,9,11,12,14,15,17,18-3H],EICOSAPENTAENOIC ACID [5,6,8 9,11,12,14,15,17,18-3 H] 9S-HYDROXY-5Z,7E,11Z,14Z,17Z-EICOSAPENTAENOIC ACID (+/-)-18-HYDROXY-5Z,8Z,11Z,14Z,16E-EICOSAPENTAENOIC ACID 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID (+/-)-11-HYDROXY-5Z,8Z,12E,14Z,17Z-EICOSAPENTAENOIC ACID (+/-)-5-HYDROXY-6E,8Z,11Z,14Z,17Z-EICOSAPENTAENOIC ACID (+/-)-8-HYDROXY-5Z,9E,11Z,14Z,17Z-EICOSAPENTAENOIC ACID

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.